July 16th, 2013
Follow-up after Barrett esophagus ablation: How do you do it, and when do you stop (if ever)?
We have shifted the paradigm of treating neoplastic Barrett esophagus (BE) away from a choice between intensive surveillance or surgery and towards endoscopic ablation. In the last 5 years, I have done hundreds of BE ablations using radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR), and many thousands have been performed worldwide. However, on post-ablation surveillance, evidence is lacking on whether and when patients can be cut loose. Moreover, I am beginning to see patients who were believed to be cured after ablation (no signs of BE or neoplasia during years of surveillance) showing up with adenocarcinoma in the distal esophagus 4 or more years later.
Until now, I have been telling my patients that once they are BE- and dysplasia-free, I want them to undergo surveillance every 4 months for 1 year, then every 6 months for 1 year, then yearly for a couple of years, and then every other year if things remain stable.
But given the uncertainties I’ve outlined above, I am interested in discussing your practices and recommendations for surveillance after ablation for BE.
On that note, what would your approach be in the following cases?
1) If a patient with high-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
2) If a patient with low-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
3) If a patient with NO dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
4) Do you ever tell patients that they are cured and no longer need surveillance (e.g., after 5 years, after 10 years, etc.)?
5) If a patient with dysplasia has their neoplastic BE completely ablated (no dysplasia but residual BE), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
Please join the discussion to shed some light on this issue.
Categories: Barrett esophagus, cancer surveillance, Patient care, practice environment, Uncategorized
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
M. Brian Fennerty, MD
Editor-in-Chief
NEJM Journal Watch Gastroenterology
Biography | Disclosures | Summaries
Learn more about Gut Check on Gastroenterology.
NEJM Resident 360 Curbside Consults Podcast
- How the Pediatric Boards Are Made with Dr. Andrew Dwyer
- Global Health, GLocal Health, and the Indian Health Service with Dr. Adriann Begay
- Immune Checkpoint Inhibitors with Dr. Kerry Reynolds
- Management of Acute Coronary Syndrome in Older Adults with Dr. Abdulla Damluji
- Culinary Medicine with Dr. Jaclyn Albin and Milette Siler, RD
-
Tag Cloud
- Ambulatory endoscopy center antiretroviral therapy Barrett esophagus boceprevir bowel preparation CMS colitis colonoscopy colorectal cancer screening CT colonography DDW drug interactions efavirenz endoscopist Endoscopy gastroenterology GI bleeding hepatitis HIV IBS Irritable Bowel Syndrome Medicare midazolam nurse Plavix PPIs primary care probiotics ritonavir Screening colonoscopy sedation sigmoidoscopy telaprevir training virtual colonoscopy